Disc Medicine (IRON) vs Vera Therapeutics (VERA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Vera Therapeutics (VERA) has outperformed Disc Medicine (IRON) over the past year, losing 2.5% versus a loss of 13.5%. Over five years, VERA leads with a +101.5% price change compared with -45.5% for IRON. Disc Medicine is the larger company by market cap ($2.33 billion vs $2.14 billion), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | IRON | VERA |
|---|---|---|
| Share price | $60.77 | $29.73 |
| Market cap | $2.33B | $2.14B |
| 1-day change | -0.67% | -1.72% |
| YTD return | -23.47% | -41.29% |
| 1-year return | -13.53% | -2.52% |
| 5-year return | -45.55% | +101.53% |
| EPS (TTM) | $-6.58 | $-5.87 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $99.50 | $56.05 |
| 52-week low | $40.00 | $23.05 |
| Distance from 52-week high | -38.92% | -46.96% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +69.77% | +160.68% |
| Average volume | 471.18K | 2.21M |
| Shares outstanding | 38.39M | 72.06M |
| Employees | 165 | 361 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- VERA has outperformed IRON by 11.0 percentage points over the past year.
About Disc Medicine
IRON stock →Disc Medicine, Inc., together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis.
Health Care · Biotechnology: Pharmaceutical Preparations · 165 employees
About Vera Therapeutics
VERA stock →Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on the development and commercialization of transformative treatments for patients with immunological diseases. The company offers atacicept, a fully humanized TACI-Fc fusion protein that binds B-cell activating factor (BAFF) and A proliferation-inducing ligand (APRIL), which is self-administered at home as a subcutaneous injection being evaluated for the treatment of immunoglobulin A nephropathy (IgAN) and other autoimmune kidney diseases.
Health Care · Biotechnology: Pharmaceutical Preparations · 361 employees
IRON vs VERA FAQ
Which is bigger, Disc Medicine or Vera Therapeutics?
Disc Medicine (IRON) is larger, with a market capitalization of $2.33B compared with $2.14B for Vera Therapeutics (VERA).
Which stock has performed better over the past year, IRON or VERA?
VERA returned -2.52% over the past 12 months, compared with -13.53% for IRON (price return, excluding dividends). Past performance does not predict future results.
Are Disc Medicine and Vera Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.